Rein Therapeutics (NASDAQ:RNTX – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports.
Separately, Weiss Ratings lowered shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $6.00.
Read Our Latest Stock Report on Rein Therapeutics
Rein Therapeutics Price Performance
Shares of NASDAQ RNTX opened at $0.36 on Wednesday. The business’s 50 day moving average is $0.69 and its two-hundred day moving average is $1.00. Rein Therapeutics has a 1-year low of $0.28 and a 1-year high of $2.10. The stock has a market capitalization of $30.75 million, a P/E ratio of -0.23 and a beta of 1.47.
Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. As a group, equities research analysts anticipate that Rein Therapeutics will post -0.47 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Rein Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the business. Chicago Partners Investment Group LLC lifted its position in shares of Rein Therapeutics by 32.2% during the first quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after purchasing an additional 10,000 shares during the last quarter. Marshall Wace LLP bought a new stake in Rein Therapeutics during the 3rd quarter valued at $127,000. Rock Creek Group LLC raised its position in Rein Therapeutics by 40.0% during the 3rd quarter. Rock Creek Group LLC now owns 175,000 shares of the company’s stock valued at $141,000 after purchasing an additional 50,000 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of Rein Therapeutics in the 2nd quarter worth $260,000. Finally, Texas Capital Bank Wealth Management Services Inc increased its stake in shares of Rein Therapeutics by 19.9% during the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 360,758 shares of the company’s stock valued at $290,000 after buying an additional 60,000 shares during the period. 90.89% of the stock is currently owned by hedge funds and other institutional investors.
About Rein Therapeutics
Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious pulmonary and fibrotic diseases. Its research focuses on therapies intended to address disease processes involved in lung injury and fibrosis. The company’s pipeline includes LTI-03, an investigational candidate being developed for idiopathic pulmonary fibrosis, and LTI-01, a candidate studied for loculated pleural effusions. These programs are investigational; they are not approved treatments.
Further Reading
- Five stocks we like better than Rein Therapeutics
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
